Stock listing
Stockholm:CINPHA Cinclus Pharma Holding AB Aktie
Home listing (Stockholm) of Cinclus Pharma Holding AB
Follow Cinclus Pharma Holding AB into a list and get an email when it puts out news.
Share price · OMXSTO:CINPHA
11.22 SEK -0.12 (-1.1%)
Close on Nov 20, 2026
- Day range
- 11.00 – 11.38 SEKNov 20, 2026
- Volume
- 46,511 sharesNov 20, 2026
- Market cap
- 522.2M SEKAt the close on Nov 20, 2026 · price × 46.54M shares outstanding
- 52-week range
- 10.48 – 19.64 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 643,125 SEKMedian day 36,033 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:CINPHA · Home | 11.22 SEK | -0.12 (-1.1%) | 46,511 | 11.38 | 11.38 | 11.00 | 11.34 | Close on Nov 20, 2026 |
| Frankfurt:J8P | €0.969 EUR | +0.002 (+0.2%) | — | €0.969 | €0.969 | €0.969 | €0.967 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:CINPHA · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 11.22 | -0.12 | -1.1% | 11.38 | 11.38 | 11.00 | 46,511 | |
| 11.34 | -0.18 | -1.6% | 11.50 | 11.66 | 11.34 | 35,870 | |
| 11.52 | -0.06 | -0.5% | 12.26 | 12.26 | 11.40 | 25,023 | |
| 11.58 | 0.00 | 0.0% | 11.76 | 11.76 | 11.40 | 34,683 | |
| 11.58 | +0.16 | +1.4% | 11.48 | 11.78 | 11.48 | 27,009 | |
| 11.42 | -0.24 | -2.1% | 11.70 | 11.82 | 11.20 | 43,753 | |
| 11.66 | -0.42 | -3.5% | 12.20 | 12.20 | 11.58 | 106,432 | |
| 12.08 | +0.58 | +5.0% | 11.84 | 12.14 | 11.20 | 93,216 | |
| 11.50 | +0.34 | +3.0% | 11.16 | 11.84 | 11.16 | 16,495 | |
| 11.16 | -0.24 | -2.1% | 11.48 | 11.48 | 11.16 | 24,382 | |
| 11.40 | -0.24 | -2.1% | 11.66 | 11.68 | 11.40 | 9,981 | |
| 11.64 | -0.34 | -2.8% | 11.96 | 11.96 | 11.50 | 52,488 | |
| 11.98 | -0.02 | -0.2% | 11.98 | 12.00 | 11.80 | 9,876 | |
| 12.00 | +0.30 | +2.6% | 11.90 | 12.12 | 11.72 | 60,843 | |
| 11.70 | -0.26 | -2.2% | 11.74 | 12.26 | 11.66 | 29,534 | |
| 11.96 | -0.04 | -0.3% | 11.88 | 12.16 | 11.70 | 34,316 | |
| 12.00 | +0.26 | +2.2% | 11.80 | 12.00 | 11.72 | 35,004 | |
| 11.74 | -0.10 | -0.8% | 12.36 | 12.36 | 11.68 | 32,523 | |
| 11.84 | -0.62 | -5.0% | 12.38 | 12.46 | 11.84 | 47,871 | |
| 12.46 | -0.30 | -2.4% | 12.76 | 12.78 | 12.38 | 19,267 | |
| 12.76 | +0.24 | +1.9% | 12.52 | 12.84 | 12.36 | 16,713 | |
| 12.52 | -0.12 | -0.9% | 12.78 | 12.78 | 12.36 | 18,282 | |
| 12.64 | -0.54 | -4.1% | 12.78 | 13.00 | 12.64 | 11,241 | |
| 13.18 | +0.24 | +1.9% | 12.96 | 13.50 | 12.52 | 30,006 | |
| 12.94 | +0.26 | +2.1% | 12.70 | 13.04 | 12.70 | 65,423 | |
| 12.68 | -0.08 | -0.6% | 12.80 | 12.98 | 12.66 | 20,082 | |
| 12.76 | -0.44 | -3.3% | 13.20 | 13.28 | 12.70 | 76,153 | |
| 13.20 | -0.26 | -1.9% | 13.14 | 13.44 | 13.10 | 20,703 | |
| 13.46 | +0.18 | +1.4% | 13.32 | 13.50 | 13.04 | 57,369 | |
| 13.28 | -0.18 | -1.3% | 13.20 | 13.50 | 13.10 | 25,250 | |
| 13.46 | -0.06 | -0.4% | 13.50 | 13.52 | 13.08 | 68,014 | |
| 13.52 | +0.58 | +4.5% | 12.88 | 13.80 | 12.80 | 104,615 | |
| 12.94 | -0.32 | -2.4% | 13.50 | 13.98 | 12.92 | 98,492 | |
| 13.26 | +0.06 | +0.5% | 13.46 | 13.80 | 13.00 | 71,939 | |
| 13.20 | +0.60 | +4.8% | 12.60 | 13.40 | 12.60 | 93,830 | |
| 12.60 | +0.64 | +5.4% | 12.00 | 12.66 | 11.88 | 107,486 | |
| 11.96 | +0.14 | +1.2% | 11.82 | 12.20 | 11.78 | 34,126 | |
| 11.82 | +0.32 | +2.8% | 11.56 | 11.88 | 11.44 | 29,551 | |
| 11.50 | -0.24 | -2.0% | 11.88 | 11.88 | 11.10 | 37,289 | |
| 11.74 | -0.02 | -0.2% | 11.68 | 11.88 | 11.52 | 15,171 | |
| 11.76 | -0.08 | -0.7% | 11.84 | 12.00 | 11.58 | 26,588 | |
| 11.84 | +0.34 | +3.0% | 11.44 | 12.08 | 11.20 | 74,164 | |
| 11.50 | -0.04 | -0.3% | 11.40 | 12.08 | 11.40 | 43,797 | |
| 11.54 | -0.06 | -0.5% | 11.60 | 11.82 | 11.20 | 26,667 | |
| 11.60 | -0.28 | -2.4% | 11.88 | 12.00 | 11.58 | 8,118 | |
| 11.88 | +0.02 | +0.2% | 12.00 | 12.12 | 11.50 | 31,236 | |
| 11.86 | -0.48 | -3.9% | 12.32 | 12.32 | 11.84 | 54,210 | |
| 12.34 | -0.14 | -1.1% | 12.40 | 12.50 | 11.98 | 16,639 | |
| 12.48 | -0.12 | -1.0% | 12.30 | 12.48 | 12.10 | 15,511 | |
| 12.60 | -0.04 | -0.3% | 12.62 | 12.66 | 12.26 | 13,270 | |
| 12.64 | +0.06 | +0.5% | 12.58 | 13.00 | 12.38 | 92,259 | |
| 12.58 | -0.04 | -0.3% | 12.50 | 12.76 | 12.40 | 28,030 | |
| 12.62 | +0.20 | +1.6% | 12.40 | 12.70 | 12.40 | 79,485 | |
| 12.42 | +0.22 | +1.8% | 12.38 | 12.80 | 12.22 | 36,196 | |
| 12.20 | -1.34 | -9.9% | 14.24 | 14.30 | 12.00 | 275,497 | |
| 13.54 | -0.46 | -3.3% | 14.00 | 14.08 | 13.28 | 142,529 | |
| 14.00 | 0.00 | 0.0% | 14.08 | 14.14 | 13.42 | 47,476 | |
| 14.00 | 0.00 | 0.0% | 14.00 | 14.42 | 13.88 | 38,251 | |
| 14.00 | +0.04 | +0.3% | 13.76 | 14.20 | 13.76 | 60,606 | |
| 13.96 | +0.26 | +1.9% | 13.52 | 14.14 | 13.48 | 68,902 | |
| 13.70 | +0.50 | +3.8% | 13.34 | 14.00 | 13.24 | 85,517 | |
| 13.20 | 0.00 | 0.0% | 13.12 | 13.38 | 13.12 | 34,820 | |
| 13.20 | +0.10 | +0.8% | 13.10 | 13.80 | 13.08 | 68,773 | |
| 13.10 | +1.22 | +10.3% | 12.02 | 13.48 | 11.90 | 116,418 |
- Ticker
- Stockholm:CINPHA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Mar 13, 2026
Cinclus Pharma Enters into EUR 28 Million Financing Agreement
Latest news
Cinclus Pharma Enters into EUR 28 Million Financing Agreement
Mar 13, 2026
Closed 17.90 (+4.8%) on Mar 13, 2026
Cinclus Pharma Holding AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Mar 13, 2026 · oldest 2026
- Decks
- 3 decks · latest Aug 20, 2025
Where Cinclus Pharma Holding AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:CINPHA · Home listing · This page | Stockholm | Sweden | SEK |
| LS Exchange:A3EN5G | LS Exchange | Germany | EUR |
| gettex:J8P | gettex | Germany | EUR |
| Munich:J8P | Munich | Germany | EUR |
| Turquoise:CINPAS | Turquoise | United Kingdom | SEK |
| Frankfurt:J8P | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3EN5G | Lang & Schwarz | Germany | EUR |
| Stuttgart:J8P | Stuttgart | Germany | EUR |
Valuation
EV/sales 3.8× against a median of 8.6×: 3rd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 134.2M SEK
- P/E
- Loss
- EV/sales
- 3.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.6×
- Gross margin
- Not reported
- Operating margin
- −830.1%
- Net margin
- −765.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.13M | US$13.15M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Aldeyra Therapeutics, Inc. · NASDAQ:ALDX | US$50.70M | US$9.72M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 0.66 |
| Clene Inc. · NASDAQ:CLNN | US$50.69M | US$58.31M | n/a | 245× | n/a | n/a | n/a | n/a | 1.48 |
| Acrivon Therapeutics, Inc. · NASDAQ:ACRV | US$49.35M | −US$26.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.09 |
| Aptamer Sciences, Inc. · KRX:291650 | US$49.20M | US$34.45M | n/a | 8.6× | n/a | 1.6× | −215.8% | 0.0× | n/a |
| Median of the others | US$51.29M | US$22.09M | 33.0× | 8.6× | 0.8× | −118.3% | 0.0× | 0.76 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 45.00 SEK · Analysts' mean
- EPS, year to Dec 2026
- -6.03 · 2 analysts
- Revenue, year to Dec 2026
- 85.93M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Christer Ahlberg | Chief Executive Officer and President |
| Magnus Christensen | Chief Financial Officer |
| Henrik Vikström | IR |
| Jesper Wiklund | Chief Business Officer |
| Kajsa Larsson | Chief Medical Officer |
| Lennart Hansson | Chairman of the Board, Co-founder |
| Peter Wallich | Commercial Director |
Board
| Director | Role |
|---|---|
| Lennart Hansson | Chairman of the Board, Co-founder |
| Anders Lundström | Non-executive Director |
| David Armstrong | Non-executive Director |
| Fredrik Johansson | Non-executive Director |
| Helena Levander | Non-executive Director |
| Torbjörn Koivisto | Non-executive Director |
| Wenche Rolfsen | Non-executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2025 | May 20, 2025 · Before open | +6.5% |
| Q4 2024 | Feb 20, 2025 · Before open | −8.1% |
| Quarter to Sep 30, 2024 | Nov 14, 2024 · Before open | −6.3% |
| Quarter to Jun 30, 2024 | Aug 29, 2024 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2025 Earnings Presentation | Earnings | 13 slides | Aug 20, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 29 slides | Nov 14, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 16 slides | Aug 29, 2024 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 57.5M | 4.58M | 5.96M | 10.6M |
| Research and development | 198.4M | 136.7M | 166.7M | 157.2M |
| Selling, general and administrative | 57.2M | 36.9M | 39.6M | 64.1M |
| Operating income | -199.6M | -169.6M | -201.0M | -210.7M |
| Depreciation and amortization | 2.38M | 1.34M | 1.25M | 1.11M |
| EBITDA | -197.2M | -168.3M | -199.7M | -209.6M |
| Interest expense | 13.9M | 28.1M | 17.2M | 76.0K |
| Income before tax | -183.7M | -167.3M | -214.6M | -231.0M |
| Net income | -184.0M | -168.0M | -215.1M | -249.1M |
| Earnings per share, basic | -3.95 | -4.54 | -8.20 | -5.35 |
| Earnings per share, diluted | -3.95 | -4.54 | -8.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 487.3M | 566.7M | 88.0M | 173.5M |
| Receivables | 16.1M | 0 | ||
| Current assets | 536.9M | 600.5M | 94.1M | 184.9M |
| Total assets | 546.6M | 601.0M | 94.4M | 185.8M |
| Accounts payable | 48.5M | 18.9M | 16.4M | 16.9M |
| Current liabilities | 136.8M | 45.5M | 164.4M | 46.1M |
| Total liabilities | 177.2M | 45.7M | 171.2M | 58.9M |
| Shareholders' equity | 369.4M | 555.3M | -76.8M | 126.9M |
| Shares outstanding | 46.5M | 46.5M | 46.5M | 46.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -74.6M | -178.4M | -209.2M | -192.1M |
| Capital spending | -1.13M | 0 | 0 | 0 |
| Free cash flow | -75.8M | -178.4M | -209.2M | -192.1M |
| Cash from investing | -1.43M | 0 | ||
| Cash from financing | -1.76M | 655.2M | 122.9M | |
| Change in cash | -77.8M | 476.8M | -86.3M | 34.1M |
Cap table
Built by 6ix from Cinclus Pharma Holding AB’s releases
- Common shares
- 46,537,789
- Fully diluted
- 46,537,789
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 46,537,789 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 46,537,789 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anders Lundström | Non-executive Director · Since at least Nov 5, 2026 |
| Christer Ahlberg | Chief Executive Officer and President · Since at least Mar 13, 2026 |
| David Armstrong | Non-executive Director · Since at least Nov 5, 2026 |
| Fredrik Johansson | Non-executive Director · Since at least Nov 5, 2026 |
| Helena Levander | Non-executive Director · Since at least Nov 5, 2026 |
| Henrik Vikström | IR · Since at least Mar 13, 2026 |
| Jesper Wiklund | Chief Business Officer · Since at least Nov 5, 2026 |
| Kajsa Larsson | Chief Medical Officer · Since at least Nov 5, 2026 |
| Lennart Hansson | Chairman of the Board, Co-founder · Since at least Nov 5, 2026 |
| Magnus Christensen | Chief Financial Officer · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Peter Wallich | Commercial Director · Since at least Nov 5, 2026 |
| Torbjörn Koivisto | Non-executive Director · Since at least Nov 5, 2026 |
| Wenche Rolfsen | Non-executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Cinclus Pharma Holding AB.